Encompass Health Corporation (EHC) Stock Price & Analysis
Encompass Health Corporation (EHC) closed at USD 126.01 on Thursday, October 22, 2026, up 4.60% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 120.47; the Oct 22, 2026 session ranged USD 119.91–126.37 on volume of 1,227,996 shares. Market capitalization is $12.43B, with a 52-week range of USD 92.77–129.96 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/EHC.md
Key facts (EHC)
- Last four reported quarters (through Jun 30, 2026): revenue $6.21B, net income $621M (10.0% margin), free cash flow $413M (SEC filings).
- Valuation: P/E 20.0x (avg 19.7x at the last 3 fiscal year-ends), net debt $2.49B.
- 1 of 80 tracked superinvestors hold EHC (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Analysts: Buy (mean 1.92 on a 1–5 scale) (13 analysts), mean target USD 148.17 (range 140–155).
- Total return with dividends: 1Y +0.4% vs S&P 500 +14.9%; 5Y +135.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-28, EPS estimate USD 1.36, revenue estimate $1.60B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (EHC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $4.01B | $4.35B | $4.80B | $5.37B | $5.94B | $6.21B |
| Operating income | $560M | $540M | — | — | — | — |
| Net income | $412M | $271M | $352M | $456M | $566M | $621M |
| EPS (diluted) | $4.11 | $2.70 | $3.47 | $4.46 | $5.54 | — |
| Free cash flow | $191M | $141M | $268M | $360M | $439M | $413M |
| Operating margin | 13.9% | 12.4% | — | — | — | — |
| Net margin | 10.3% | 6.2% | 7.3% | 8.5% | 9.5% | 10.0% |
| Revenue growth | +12.6% | +8.3% | +10.4% | +11.9% | +10.5% | — |
| Cash + short-term investments | $49.4M | $21.8M | $69.1M | $85.4M | $72.2M | — |
| Total debt | $3.24B | $2.74B | $2.69B | $2.36B | $2.45B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (EHC)
P/E 20.0x · P/S 2.0x · EV/Sales 2.4x · P/FCF 30.1x · P/B 4.8x · FCF yield 3.33% · Earnings yield 5.00% · Dividend yield (paid, TTM) 0.60% · Buyback yield (TTM) 1.99% · Net debt $2.49B · EV $14.9B
P/E at fiscal year-ends: Dec 2025 19.2x, Dec 2024 20.7x, Dec 2023 19.2x.
Superinvestors (SEC 13F-HR, Q2 2026) (EHC)
1 of 80 tracked investors hold EHC. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Jensen Investment Management | 0.10% | $4.0M | Reduced -22.5% |
Analysts (EHC)
Consensus Buy (mean 1.92 on a 1–5 scale), 13 analysts; mean target USD 148.17 (low 140, high 155).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-10 | TD Cowen | Target raised | Buy | $125 → $140 |
| 2026-08-07 | UBS | Target raised | Buy | $150 → $155 |
| 2026-08-07 | Truist Securities | Target raised | Buy | $140 → $150 |
| 2026-08-06 | Barclays | Target raised | Overweight | $140 → $144 |
Total return (dividends reinvested) (EHC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +0.4% | +135.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +0.4% | +18.6% |
| Volatility (annualized) | 29.4% | 26.1% |
| Max drawdown | -26.1% (Oct 2025→Feb 2026) | -25.1% (Sep 2025→Jan 2026) |
EHC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.36 | $1.36 | -0.1% | $1.60B | 12 |
| Next quarter (ends Dec 2026) | $1.61 | $1.57 | +2.5% | $1.67B | 12 |
| Current fiscal year (ends Dec 2026) | $6.11 | $6.01 | +1.8% | $6.46B | 13 |
| Next fiscal year (ends Dec 2027) | $6.68 | $6.54 | +2.2% | $6.99B | 13 |
Key Statistics (as of October 23, 2026 at 10:11 UTC)
| Price | USD 126.01 |
|---|---|
| Change | ▲ 4.60% (up) |
| Previous Close | USD 120.47 |
| Open | USD 121.13 |
| Day Range | USD 119.91 – 126.37 |
| 52-Week Range | USD 92.77 – 129.96 |
| Volume | 1,227,996 shares |
| Market Cap | $12.43B |
| Exchange | NYQ |
Technical Analysis (EHC)
Nexqual's technical model rates EHC "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 10:11 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.58 (neutral) |
| vs SMA50 | Above (USD 122.34) |
| MACD | 0.65 (positive) |
Analyst Ratings (EHC)
Wall Street analysts rate EHC "Buy" based on 13 analysts, with a mean price target of USD 148.17 (range USD 140–155), per Nexqual as of October 23, 2026 at 10:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 148.17 |
| High Target | USD 155 |
| Low Target | USD 140 |
| Buy / Hold / Sell | 13 / 0 / 0 |
Earnings (EHC)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD 1.36 |
| Revenue Estimate | $1.60B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.55 vs est 1.48 ▲ beat |
| 2026-03-31 | USD 1.6 vs est 1.49 ▲ beat |
| 2025-12-31 | USD 1.46 vs est 1.3 ▲ beat |
| 2025-09-30 | USD 1.23 vs est 1.19 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financials & Fundamentals (EHC)
| Total Revenue | $6.21B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +9.60% |
| Gross Margin | +43.86% |
| Operating Margin | +18.05% |
| Profit Margin | +10.01% |
| ROE | +24.97% |
| Debt / Equity | 0.82 |
| Current Ratio | 1.19 |
| Total Cash | $107.70M |
| Total Debt | $2.84B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $413.40M (6.7% of revenue) |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financial Health Score (EHC)
Nexqual rates Encompass Health Corporation's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 10:11 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 44%, operating 18% (last 12 months) |
| Balance Sheet | Mixed — $108M cash and investments vs $2.60B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $413M (last 4 quarters to Jun 2026, SEC), 7% margin |
| Efficiency | Strong — ROE 25%, ROA 9.8% |
Ownership (EHC)
| Insider Ownership | +0.87% |
|---|---|
| Institutional Ownership | +100.81% |
| Shares Outstanding | 98.65M |
| Float | 97.65M |
| Short % of Float | +3.99% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Leadership (EHC)
Encompass Health Corporation is led by Mark J. Tarr, CEO, President & Director, per Nexqual as of October 23, 2026 at 10:11 UTC.
| CEO, President & Director | Mark J. Tarr |
|---|---|
| Executive VP & CFO | Douglas E. Coltharp |
| Executive VP & COO | Patrick W. Tuer |
| Senior Vice President of Investor Relations & Strategic Planning | Mark Miller |
Major Backers & Investors (EHC)
Notable institutional backers of Encompass Health Corporation include Price (T.Rowe) Associates Inc, Wellington Management, Citadel, according to Nexqual as of October 23, 2026 at 10:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 5.12% |
| Wellington Management | 3.32% |
| Citadel | 2.6% |
| Alliancebernstein L.P. | 2.51% |
| Fuller & Thaler Asset Management Inc. | 2.49% |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund | 2.38% |
| Two Sigma Investments, LP | 2.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.63% |
| Vanguard Group | 9.53% |
| State Street | 3.23% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DVA | DaVita Inc. | USD 186.1 | ▲ 5.25% |
| FMS | Fresenius Medical Care AG | USD 22.23 | ▲ 3.11% |
| UHS | Universal Health Services, Inc. | USD 188.13 | ▲ 2.88% |
| ENSG | The Ensign Group, Inc. | USD 178.35 | ▲ 2.88% |
| PACS | PACS Group, Inc. | USD 47.5 | ▲ 1.58% |
| THC | Tenet Healthcare Corporation | USD 270.63 | ▲ 0.56% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt